Verrica Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.29
Dividend & YieldN/A$ (N/A)
Beta 1.93
Market capitalization 108.9M
Operating cash flow -22.39M
ESG Scores unknown

Company description

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 793k 225k -338k -3k
Total Cashflows From Investing Activities -79.89M 25.95M -3.58M -998k
Net Borrowings 34.46M 34.46M 34.46M 4.97M
Total Cash From Financing Activities 99.38M 423k 35.23M 33.65M
Change To Operating Activities 145k -1.95M 1.97M -532k
Issuance Of Stock 86.26M 423k 453k 28.68M
Net Income -20.65M -28.21M -42.69M -35.08M
Change In Cash 1.61M -1.03M 1.45M 5.07M
Effect Of Exchange Rate
Total Cash From Operating Activities -17.87M -27.41M -30.21M -27.58M
Depreciation 20k 257k 229k 472k
Change To Account Receivables
Other Cashflows From Financing Activities -7.88M 319k 319k
Change To Netincome 1.82M 2.27M 10.62M 7.56M
Capital Expenditures -774k -682k -1.47M -883k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 12.83M 15.44M 15.67M 15.93M
Income Before Tax -20.65M -28.21M -42.69M -35.08M
Net Income -20.65M -28.21M -42.69M -35.08M
Selling General Administrative 9.05M 14.64M 24.51M 26.98M
Gross Profit 12M
Ebit -21.88M -30.08M -40.18M -30.91M
Operating Income -21.88M -30.08M -40.18M -30.91M
Interest Expense -3.03M -3.03M -3.03M -4.29M
Income Tax Expense
Total Revenue 12M
Cost Of Revenue
Total Other Income ExpenseNet 1.23M 1.87M -2.51M -4.17M
Net Income From Continuing Ops -20.65M -28.21M -42.69M -35.08M
Net Income Applicable To Common Shares -20.65M -28.21M -42.69M -35.08M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.48M 3.41M 41.17M 47.52M
Total Stockholder Equity 89.43M 65.02M 32.99M 32.6M
Other Current Liabilities 777k 255k
Total Assets 91.91M 68.42M 74.15M 80.12M
Common Stock 3k 3k 3k 3k
Other Current Assets
Retained Earnings -33.08M -61.19M -103.89M -138.97M
Treasury Stock -17k -390k 1k -29k
Cash 10.27M 9.24M 10.69M 15.75M
Total Current Liabilities 2.48M 3.35M 39.48M 46.05M
Other Stockholder Equity -17k -390k 1k -29k
Property, Plant, and Equipment 255k 2.2M 4.94M 5.5M
Total Current Assets 91.15M 64.98M 67.65M 74.33M
Net Tangible Assets 89.43M 65.02M 32.99M 32.6M
Net Receivables
Accounts Payable 922k 1.19M 348k 845k


Insider Transactions

Here are the insider transactions of stock shares related to Verrica Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
HAYES CHRISTOPHER GPurchase at price 3.40 per share.D2022-07-11Officer7.5k
PERCEPTIVE ADVISORS L L CPurchase at price 2.10 per share.I2022-07-05Beneficial Owner of more than 10% of a Class of Security1.43M
MANNING PAUL B.Purchase at price 2.10 per share.D2022-07-05Director and Beneficial Owner of more than 10% of a Class of Security4.76M
STALFORT JOHN A IIIPurchase at price 2.10 per share.D2022-07-05Director238.09k
WHITE TED W.Purchase at price 2.10 per share.D2022-07-05Chief Executive Officer23.81k
GOLDENBERG GARYPurchase at price 2.10 per share.D2022-07-05Officer23.81k
HAYES CHRISTOPHER GPurchase at price 2.10 per share.D2022-07-05Officer5.71k
MANNING PAUL B.Purchase at price 9.22 - 9.45 per share.D2021-12-03Director and Beneficial Owner of more than 10% of a Class of Security50k
MANNING PAUL B.Stock Gift at price 0.00 per share.I2021-07-06Director and Beneficial Owner of more than 10% of a Class of Security739.83k
DAVIS A BRIANPurchase at price 9.89 per share.D2021-06-04Chief Financial Officer5k
WHITE TED W.Purchase at price 9.95 per share.D2021-06-04Chief Executive Officer4k
HAYES CHRISTOPHER GPurchase at price 9.79 per share.D2021-06-04Officer2.5k
MANNING PAUL B.Purchase at price 14.75 per share.I2021-03-25Director and Beneficial Owner of more than 10% of a Class of Security739.83k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Verrica Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Verrica Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Verrica Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Verrica Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Verrica Pharmaceuticals Inc:

Verrica Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 3.27% on the backtest period.

Performance at glance

Performance

3.27 %

Latent gain

49.28 $

Invested capital

1508.48 $

Annualized return

0.96 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Verrica Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Verrica Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Verrica Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Verrica Pharmaceuticals Inc:

Verrica Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give 18.01% of return on Verrica Pharmaceuticals Inc. That represents 809.81$ of latent gain with 4496.31$ of employed capital.
  • The second momentum investment strategy would give 24.2% of return on Verrica Pharmaceuticals Inc. That represents 547.7$ of latent gain with 2263.57$ of employed capital.
Performance at glance (1Q Momentum)

Performance

18.01 %

Latent gain

809.81 $

Invested capital

4496.31 $

Annualized return

13.44 %
Performance at glance (2Q Momentum)

Performance

24.2 %

Latent gain

547.7 $

Invested capital

2263.57 $

Annualized return

8.29 %

Momentum equity curve on Verrica Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Verrica Pharmaceuticals Inc:

Verrica Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Verrica Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Verrica Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Verrica Pharmaceuticals Inc since the beginning:

Verrica Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Verrica Pharmaceuticals Inc

Buy the dip entry openings on Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc

The performance achieved by the robo-advisor on Verrica Pharmaceuticals Inc is 18.81%. That represents 140.65$ of latent gain with 747.76$ of employed capital. The following chart shows Verrica Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Verrica Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

18.81 %

Latent gain

140.65 $

Invested capital

747.76 $

Annualized return

13.44 %

Equity curve of the strategy applied to Verrica Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Verrica Pharmaceuticals Inc:

Verrica Pharmaceuticals Inc

Note: the dividends potentially given by Verrica Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Verrica Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Verrica Pharmaceuticals Inc:

Verrica Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Verrica Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Verrica Pharmaceuticals Inc.

Equity curve comparison on Verrica Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Verrica Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc investment comparison

Performance comparison on Verrica Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 3.27% 49.28$ 1508.48$ 0.96%
Momentum 1 quarter 18.01% 809.81$ 4496.31$ 5.7%
Momentum 2 quarters 24.2% 547.7$ 2263.57$ 8.29%
Non-directional 18.81% 140.65$ 747.76$ 13.44%
Annualized return comparison

Automatic investment

0.96 %

Momentum 1Q

8.29 %

Momentum 2Q

8.29 %

Non-directional

13.44 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Verrica Pharmaceuticals Inc:

Positive correlations

Most correlated stocks this year

  • Verrica Pharmaceuticals Inc

  • Most correlated stocks last 3 months

  • Verrica Pharmaceuticals Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Verrica Pharmaceuticals Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Verrica Pharmaceuticals Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Verrica Pharmaceuticals Inc
    Country United States
    City West Chester
    Address 44 West Gay Street
    Phone 484 453 3300
    Website www.verrica.com
    FullTime employees 38
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker VRCA
    Market www.nasdaq.com

    Verrica Pharmaceuticals Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown